Document and Entity Information
Document and Entity Information | Dec. 07, 2023 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001347178 |
Document Type | 8-K/A |
Document Period End Date | Dec. 07, 2023 |
Entity Registrant Name | VANDA PHARMACEUTICALS INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-34186 |
Entity Tax Identification Number | 03-0491827 |
Entity Address, Address Line One | 2200 Pennsylvania Avenue NW |
Entity Address, Address Line Two | Suite 300E |
Entity Address, City or Town | Washington |
Entity Address, State or Province | DC |
Entity Address, Postal Zip Code | 20037 |
City Area Code | (202) |
Local Phone Number | 734-3400 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | VNDA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K of Vanda Pharmaceuticals Inc. (“Vanda”), filed on December 7, 2023 (the “Original Report”), in which Vanda reported the acquisition from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (“Janssen”), of the U.S. and Canadian rights for PONVORY® (ponesimod) (the “Acquired Business”), pursuant to the terms of that certain Asset Purchase Agreement, dated as of December 7, 2023 by and between Vanda and Janssen. This Amendment No. 1 is being filed by Vanda to amend the Original Report solely to provide the financial statement and financial information required by Item 9.01 of Form 8-K that were not filed with the Original Report. |